From the *Loyola University Chicago, Maywood, Illinois
†Baptist Health Heart and Transplant Institute, Little Rock, Arkansas
‡Duke University, Durham, North Carolina
§The Johns Hopkins Hospital, Baltimore, Maryland
¶Vanderbilt, Nashville, Tennessee
∥Christ Hospital, Cincinnati, Ohio
#Inova Heart and Vascular Institute, Falls Church, Virginia
**University of Colorado, Aurora, Colorado
††Columbia University, New York, New York
‡‡Abbott (Formerly Thoratec, St Jude Medical), Chicago, Illinois.
Submitted for consideration October 2021; accepted for publication in revised form June 2022.
Disclosure: A.K. and N.U.: Consultant – Abbott. J.L.: Consultant - Novartis, Abbott, Relypsa, and Resmed. P.S.: research grants - AHA/Enduring Hearts, Haemonetics, Medtronic, and Merck. D.C. and D.J.F.: Employee – Abbott. J.M.W.: research grant – Abbott. The remaining authors have no conflicts of interest to report.
This study (NCT02158403) was funded by Thoratec (now part of Abbott).
Correspondence: Jeanine M. Walenga, PhD, Health Sciences Division, Cardiovascular Research Institute, CTRE-434, Loyola University Chicago, 2160 S. First Avenue, Maywood, IL 60153. E-mail: [email protected].